Biocon Q3 profit after tax seen up 15% to Rs 93 cr

Indian biotechnology firm Biocon is set to announce its results for the quarter ended December 2010. According to CNBC-TV18 estimates, its profit after tax is expected go  up by 15% to Rs 93 crore in Q3FY11 as against Rs 80.9 crore in same period of previous year.

Revenues are seen going up by 11.7% to Rs 710 crore from Rs 635 crore. Operating profit margin is seen improving at 21% versus 19.9%. Watch out for:
-Topline growth led by Biopharma division + AxiCorp (German subsidiary)
-Biopharma to be led by domestic formuls statins, insulin, immunosuppresants (up 16% in Q2 to Rs 578 crore)
-Growth in Axicorp led by generic tender business with products such as Metformin, Metoporolol, Flucanoze (Axicorp grew 24% in Q2 to Rs 260 crore)
-CRAMS likely to pick up going forward; grew 6.7% in Q2 to Rs 78 crore
-Watch for licensing income (was Rs 23 cr in Q2 from Mylan while 1HFY11 licensing income Rs 43.7 crore
-Margin expansion on the back of better product mix and licensing income (flows directly to EBITDA)
-Watch for R&D expenses